Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport?

Pharmaceutical Research

Volumn 19, Issue 4, 2002, Pages 457-462

  Susanto, Miki ^a   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cefsulodin; Cystic fibrosis; Dicloxacillin; P glycoprotein; Renal clearance; Sulfamethoxazole; Trimethoprim

Indexed keywords

ANTIBIOTIC AGENT; CEFSULODIN; CYCLOSPORIN; DICLOXACILLIN; ELACRIDAR; GLYCOPROTEIN P; KETOCONAZOLE; MANNITOL; SULFAMETHOXAZOLE; TETRYLAMMONIUM CHLORIDE; TRIMETHOPRIM; VINBLASTINE;

ANIMAL CELL; ARTICLE; CELL STRAIN; CYSTIC FIBROSIS; ELECTRIC RESISTANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY CLEARANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT;

ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT; CELL LINE; CYSTIC FIBROSIS; HUMANS; KIDNEY; METABOLIC CLEARANCE RATE; P-GLYCOPROTEIN;

EID: 0036108454     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015191511817     Document Type: Article

References (30)

1. Cystic Fibrosis
2. Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis
3. Pharmacokinetics of methicillin in patients with cystic fibrosis
4. Cloxacillin absorption and disposition in cystic fibrosis
5. Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim
6. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: A controlled prospective study
7. Disposition of drugs in cystic fibrosis. IV. Mechanisms for enhanced renal clearance of ticarcillin
8. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance
9. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis
10. Drug disposition in cystic fibrosis
11. High dose treatment with antibiotics in cystic fibrosis - A reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients
12. Pharmacokinetics of drugs in cystic fibrosis
13. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis
14. Difference in renal handling of cefsulodin between patients with cystic fibrosis and normal subjects
15. Ceftazidime disposition in acute and stable cystic fibrosis
16. Disposition of tobramycin in patients with cystic fibrosis: A prospective controlled study
17. Assessment of glomerular filtration rate and effective renal plasma flow in cystic fibrosis
18. Renal function in cystic fibrosis with special reference to the renal sodium handling
19. Increased renal clearance of cefsulodin due to higher glomerular filtration rate in cystic fibrosis
20. Effect on renal function of essential fatty acid supplementation in cystic fibrosis
21. Induction of multidrug resistance downregulates the expression of CFTR in colon epithelial cells
22. The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression
23. Co-ordinate regulation of the cystic fibrosis and multidrug resistance genes in cystic fibrosis knockout mice
24. Quantitative expression patterns of multidrug-resistance P-glycoprotein (MDR1) and differentially spliced cystic-fibrosis transmembrane- conductance regulator mRNA transcripts in human epithelia
25. Phosphorylation of P-glycoprotein by PKA and PKC modulates swelling- activated Cl- currents
26. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells
27. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1- MDCK and Caco-2 cell monolayers
28. Hospital routine analysis of penicillins. Third-generation cephalosporins and aztreonam by conventional and high-speed high- performance liquid chromatography
29. Investigating the role of P-glycoprotein on drugs exhibiting enhanced renal clearance in cystic fibrosis patients
30. Rational use of in vitro p-glycoprotein assays in drug discovery